Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells

Cancer Cell

Volumn 7, Issue 6, 2005, Pages 547-559

  Yang, Yili ^a   Ludwig, Robert L ^b   Jensen, Jane P ^a   Pierre, Shervon A ^a   Medaglia, Maxine V ^a   Davydov, Ilia V ^c   Safiran, Yassamin J ^c   Oberoi, Pankaj ^c   Kenten, John H ^c   Phillips, Andrew C ^d   Weissman, Allan M ^a   Vousden, Karen H ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c American Dental Association Science and Research Institute   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 (3 CHLOROPHENYL) 7 NITRO 10H PYRIMIDO[4,5 B]QUINOLINE 2,4 DIONE; 10 (4 CHLOROPHENYL) 7 NITRO 10H PYRIMIDO[4,5 B]QUINOLINE 2,4 DIONE; 10 (4 METHYLPHENYL) 7 NITRO 10H PYRIMIDO[4,5 B]QUINOLINE 2,4 DIONE; ALDEHYDE PROTEASOME INHIBITOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOXORUBICIN; LIGASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN P53; THIOESTER; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STABILITY; TOXICITY;

EID: 20444369867     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.04.029     Document Type: Article

References (66)

1. J. Adams The development of proteasome inhibitors as anticancer drugs Cancer Cell 5 2004 417 421
2. M. Ashcroft, Y. Taya, and K.H. Vousden Stress signals utilize multiple pathways to stabilize p53 Mol. Cell. Biol. 20 2000 3224 3233
3. KIP2 expression by p73β Proc. Natl. Acad. Sci. USA 99 2002 3529 3534
4. M. Bendjennat, J. Boulaire, T. Jascur, H. Brickner, V. Barbier, A. Sarasin, A. Fotedar, and R. Fotedar UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair Cell 114 2003 599 610
5. J. Bloom, V. Amador, F. Bartolini, G. DeMartino, and M. Pagano Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation Cell 115 2003 71 82
6. J. Chen, J. Lin, and A.J. Levine Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene Mol. Med. 1 1995 142 152
7. Z. Chen, J. Hagler, V.J. Palombella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway Genes Dev. 9 1995 1586 1597
8. K. Chen, A. Albano, A. Ho, and J.F.J. Keaney Activation of p53 by oxidative stress involved platelet-derived growth factor-beta receptor mediated ataxia telangiectasia mutated (ATM) kinase activation J. Biol. Chem. 278 2003 39527 39533
9. P. Chene Inhibiting the p53-MDM2 interaction Nat. Rev. Cancer 3 2003 102 109
10. J.E. Chipuk, and D.R. Green p53's believe it or not: Lessons on transcription-independent death J. Clin. Immunol. 23 2003 355 361
11. D.J. Clarke Proteolysis and the cell cycle Cell Cycle 1 2002 233 234
12. P. Coulombe, G. Rodier, F. Bonneil, P. Thibault, and S. Meloche N-terminal ubiquitination of thet extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome Mol. Cell. Biol. 24 2004 6140 6150
13. Dai, M.S., and Lu, H. (2004). Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J. Biol. in press.
14. M.S. Dai, S.X. Zeng, Y. Jin, X.X. Sun, L. David, and H. Lu Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition Mol. Biol. Cell 24 2004 7654 7668
15. I.V. Davydov, D. Woods, Y.J. Safiran, P. Oberol, H.O. Fearnhead, S. Fang, J.P. Jensen, A.M. Weissman, J.H. Kenten, and K.H. Vousden Assay for ubiquitin ligase activity: High-throughput screen for inhibitors of HDM2 J. Biomol. Screen. 9 2004 695 703
16. D. Dornan, I. Wertz, H. Shimizu, D. Arnott, G.D. Frantz, P. Dowd, K. O'Rourke, H. Koeppen, and V.M. Dixit The ubiquitin ligase COP1 is a critical negative regulator of p53 Nature 429 2004 86 92
17. S.A. Ettenberg, A. Magnifico, M. Cuello, M.M. Nau, Y.R. Rubinstein, Y. Yarden, A.M. Weissman, and S. Lilowitz Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex J. Biol. Chem. 276 2001 27677 27684
18. S. Fang, and A.M. Weissman A field guide to ubiquitylation Cell. Mol. Life Sci. 61 2004 1546 1561
19. S. Fang, J.P. Jensen, R.L. Ludwig, K.H. Vousden, and A.M. Weissman Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53 J. Biol. Chem. 275 2000 8945 8951
20. A. Fazeli, R.G. Steen, S.L. Dickinson, D. Bautista, W.F. Dietrich, R.T. Bronson, R.S. Bresalier, E.S. Lander, J. Costa, and R.A. Weinberg Effects of p53 mutations in apoptosis in mouse intestinal and human colonic adenomas Proc. Natl. Acad. Sci. USA 94 1997 10199 10204
21. J. Gu, N. Nie, D. Wiederschain, and Z.-M. Yuan Identification of p53 sequence elements that are required for MDM2-mediated nuclear export Mol. Cell. Biol. 21 2001 8533 8546
22. S. Haupt, and Y. Haupt Improving cancer therapy through p53 management Cell Cycle 3 2004 912 916
23. G. Hu, and E.R. Fearon Siah-1 N-terminal RING domain is required for proteolysis function, and C-terminal sequences regulate oligomerization and binding to target proteins Mol. Cell. Biol. 19 1999 724 732
24. N. Issaeva, P. Bozko, M. Enge, M. Protopopova, L.G. Verhoef, M. Masucci, A. Pramanik, and G. Selinova Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors Nat. Med. 10 2004 1321 1328
25. A. Jin, K. Itahana, K. O'Keefe, and Y. Zhang Inhibition of HDM2 and activation of p53 by ribosomal protein L23 Mol. Cell. Biol. 24 2004 7669 7680
26. S.N. Jones, A.E. Roe, L.A. Donehower, and A. Bradley Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 378 1995 206 208
27. S.E. Kern, J.A. Pietenpol, S. Thiagalingam, A. Seymour, K.W. Kinzler, and B. Vogelstein Oncogenic forms of p53 inhibit p53-regulated gene expression Science 256 1992 827 830
28. M.H.G. Kubbutat, S.N. Jones, and K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303
29. Z. Lai, T. Yang, Y.B. Kim, T.M. Sielecki, M.A. Diamond, P. Strack, M. Rolfe, M. Caligiuri, P.A. Benfield, K.R. Auger, and R.A. Copeland Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors Proc. Natl. Acad. Sci. USA 99 2002 14734 14739
30. D.P. Lane, and S. Lain Therapeutic exploitation of the p53 pathway Trends Mol. Med. 8 2002 S38 S42
31. R.P. Leng, Y. Lin, W. Ma, H. Wu, B. Lemmers, S. Chung, J.M. Parant, G. Lozano, R. Hakem, and S. Benchimol Pirh2, a p53-inducible ubiquitin-protein ligase, promotes p53 degradation Cell 112 2003 779 791
32. M. Li, C.L. Brooks, F. Wu-Baer, D. Chen, R. Baer, and W. Gu Mono- versus polyubiquitination: Differential control of p53 fate by Mdm2 Science 302 2003 1972 1975
33. G. Liu, J.M. Parant, G. Lang, P. Chau, A. Chavez-Reyes, A.K. El-Naggar, A. Multani, S. Chang, and G. Lozano Chromosomal stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice Nat. Genet. 36 2004 63 68
34. M. Ljungman Dial 9-1-1 for p53: Mechanisms of p53 activation by cellular stress Neoplasia 2 2000 208 225
35. M.A.E. Lohrum, D.B. Woods, R.L. Ludwig, E. Bálint, and K.H. Vousden C-terminal ubiquitination of p53 contributes to nuclear export Mol. Cell. Biol. 21 2001 8521 8532
36. M.A. Lohrum, R.L. Ludwig, M.H.G. Kubbutat, M. Hanlon, and K.H. Vousden Regulation of HDM2 activity by the ribosomal protein L11 Cancer Cell 3 2003 577 587
37. K.L. Lorick, J.P. Jensen, S. Fang, A.M. Ong, S. Hatakeyama, and A.M. Weissman RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination Proc. Natl. Acad. Sci. USA 96 1999 11364 11369
38. S.W. Lowe, H.E. Ruley, T. Jacks, and D.E. Housman p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
39. D.W. Meek, and U. Knippschild Posttranslational modifications of MDM2 Mol. Cancer Res. 1 2003 1017 1026
40. S.M. Mendrysa, M.K. McElwee, J. Michalowski, K.A. O'Leary, K.M. Young, and M.E. Perry mdm2 is critical for inhibition of p53 during lympopoiesis and the response to ionizing irradiation Mol. Cell. Biol. 23 2003 462 472
41. D. Michael, and M. Oren The p53-Mdm2 module and the ubiquitin system Semin. Cancer Biol. 13 2003 49 58
42. M. Mihara, S. Erster, A. Zaika, O. Petrenko, T. Chittenden, P. Pancoska, and U.M. Moll p53 has a direct apoptogenic role at the mitochondria Mol. Cell 11 2003 577 590
43. K. Nakano, E. Balint, M. Ashcroft, and K.H. Vousden A ribonucleotide reductase gene is a transcriptional target of p53 and p73 Oncogene 19 2000 4283 4289
44. S. Rowan, R.L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K.H. Vousden Specific loss of apoptotic but not cell cycle arrest function in a human tumour derived p53 mutant EMBO J. 15 1996 827 838
45. K.M. Ryan, J. O'Prey, and K.H. Vousden Loss of nuclear factor-kappaB is tumor promoting but does not substitute for loss of p53 Cancer Res. 64 2004 4415 4418
46. M. Scheffner, J.M. Huibregtse, R.D. Vierstra, and P.M. Howley The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 Cell 75 1993 495 505
47. M. Scheffner, J.M. Huibregtse, and P.M. Howley Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53 Proc. Natl. Acad. Sci. USA 91 1994 8797 8801
48. C.A. Schmitt, S.J. Fridman, M. Yang, E. Baranov, R.M. Hoffman, and S.W. Lowe Dissecting p53 tumor suppressor functions in vivo Cancer Cell 1 2002 289 298
49. G. Selinova Mutant p53: The loaded gun Curr. Opin. Investig. Drugs 2 2001 1136 1141
50. R.J. Sheaff, J.D. Singer, J. Swanger, M. Smitherman, J.M. Roberts, and B.E. Clurman Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination Mol. Cell 5 2000 403 410
51. C.J. Sherr, and J.D. Weber The ARF/p53 pathway Curr. Opin. Genet. Dev. 10 2000 94 99
52. S.-Y. Shieh, M. Ikeda, Y. Taya, and C. Prives DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2 Cell 91 1997 325 334
53. J.D. Siliciano, C.E. Canman, Y. Taya, K. Sakaguchi, E. Appella, and M.B. Kastan DNA damage induces phosphorylation of the amino terminus of p53 Genes Dev. 11 1997 3471 3481
54. J.M. Stommel, and G.M. Wahl Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation EMBO J. 23 2004 1547 1556
55. H. Symonds, L. Krall, L. Remington, M. Saenzrobles, S. Lowe, T. Jacks, and T. Van Dyke p53-dependent apoptosis suppresses tumor growth and progression in vivo Cell 78 1994 703 711
56. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. King, U. Kammlott, C. Lukacs, and C. Klein In vivo activation of the p53 pathway by small-molecular antagonists of MDM2 Science 303 2004 844 848
57. B. Vogelstein, D. Lane, and A.J. Levine Surfing the p53 network Nature 408 2000 307 310
58. K.H. Vousden Activation of the p53 tumor suppressor gene Biochim. Biophys. Acta 1602 2002 47 59
59. K.H. Vousden, and X. Lu Live or let die: The cell's response to p53 Nat. Rev. Cancer 2 2002 594 604
60. A.M. Weissman Themes and variations on ubiquitylation Nat. Rev. Mol. Cell Biol. 2 2001 169 178
61. S.A. Williams, and D.J. McConkey The proteasome inhibitor bortezomib stabilizes a novel active form of p53 in human LNCaP-Pro5 prostate cancer cells Cancer Res. 63 2003 7338 7344
62. D.P. Xirodimas, M.K. Saville, J.C. Bourdon, R.T. Hay, and D.P. Lane Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity Cell 118 2004 83 97
63. Y. Xu Regulation of p53 responses by post-translational modifications Cell Death Differ. 10 2003 400 403
64. Y. Yang, and X. Yu Regulation of apoptosis: The ubiquitous way FASEB J. 17 2003 790 799
65. Y. Yang, Z. Liu, E. Tolosa, J. Yang, and L. Li Triptolide induces apoptotic death of T lymphocytes Immunopharmacology 40 1998 139 149
66. Y. Zhang, G.W. Wolf, K. Bhat, A. Jin, T. Allio, W.A. Burkhart, and Y. Xiong Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway Mol. Cell. Biol. 23 2003 8902 8912